Xarelto – a relatively new anticoagulant medication – has been linked to severe side effects and adverse reactions such as uncontrollable bleeding and an increased risk of blood clots. Patients who have suffered harmful side effects after taking Xarelto will be looking for a drug injury law firm for legal assistance. Broughton Partners connects personal injury law firms with Xarelto lawsuit leads and other drug injury leads. We deliver qualifed retainers pre-packaged with the necessary files to work the case. Law firms looking for more Xarelto lawsuit leads can work with Broughton Partners and start receiving Xarelto lawsuit leads that fit their specific case criteria.
Xarelto (rivaroxaban) was first approved by the FDA in July of 2011. Blood thinners have three main uses:
- Reducing the risk of blood clots and stroke in patients with atrial fibrillation,
- Treating deep vein thrombosis and pulmonary embolisms, and
- Reducing the risk of blood clots in patients undergoing knee or hip replacement surgery.
To treat a clotting disorder (which can lead to strokes or embolisms), a medication like Xarelto may be prescribed which will keep the blood from clotting. As a result of the action of this drug, patients must be very careful to avoid injury, as the blood can no longer clot naturally.
Patients must be very careful to avoid injury, as the blood can no longer clot naturally.
Older blood thinners like Warfarin (Coumadin) have been around for over 50 years. Warfarin has an antidote, and its blood-thinning effects can be reversed with a shot of Vitamin K.
Unlike Warfarin, Xarelto does not have an antidote. If a patient taking Xarelto is injured or needs surgery, there is no shot that will reverse its effects and allow the body to resume clotting normally. Patients who begin hemorrhaging while taking Xarelto may not be able to stop, leading to massive blood loss and possibly death.
Over 20,000 patients have filed lawsuits against the manufacturers of Xarelto claiming the anticoagulant has caused them to suffer serious side effects.
Bayer and Johnson & Johnson’s Janssen Pharmaceuticals, Inc. are facing several Xarelto lawsuits alleging that the drug is dangerous and that the manufacturer failed to warn consumers about the risks. Lawsuits claim that doctors have no effective means of combating bleeding in the event of an emergency.
Furthermore, lawsuits filed claim that the manufacturers marketed Xarelto as a superior anticoagulant despite a number of adverse events reported to the FDA. Doctors and medical staff were also allegedly not properly made aware of the risks and how to treat someone using Xarelto in the event of bleeding complications.
Families rely on doctors and medication to keep them healthy. If Xarelto’s manufacturer failed to inform a patient or doctor of the potential side effects, or if a patient has suffered unforeseen adverse reactions after taking Xarelto, they may have grounds to pursue a Xarelto claim and or a Xarelto lawsuit.
Victims of a Xarelto bleeding event may be entitled to compensation for past and future medical bills, lost wages and, their pain and suffering. Broughton Partners works to connect these Xarelto victims and other victims of dangerous drugs with personal injury law firms.
Rivaroxaban, an anticoagulant, was submitted to the FDA for approval in the United States of America.
The FDA advisory committee found a favorable risk to benefit profile for the drug for use after some knee and hip surgeries to help prevent or reduce the risk of DVT (Deep Vein Thrombosis) or Pulmonary Embolism.
The FDA approved Xarelto, the brand name for the generic drug Rivaroxaban. Later that same year, the FDA approved Xarelto to prevent Stroke in people with certain types of Abnormal Heart Rhythm.
The FDA approved expanded use of Xarelto to treat and/or reduce the occurrence of blood clots.
At least six lawsuits were filed related to the use of Xarelto. The claimants all listed excessive or hemorrhagic bleeding after the prescribed use of the drug.
Claims were brought against Bayer and Johnson & Johnson in relation to excessive bleeding, but in October of 2015, the first suit was brought claiming that the drug failed to prevent stroke. The claimant filed suit on behalf of her father, who died four days after being prescribed and using Xarelto for Atrial Fibrillation.
CBS News reported on controversial Xarelto research by the Duke Clinical Research Institute and findings that may have been withheld. The controversy surrounds results shared the possibility that the results may have been skewed by faulty testing equipment. The original testing was used to measure Xarelto’s effectiveness against Warfarin, another more common clotting drug.
The FDA failed to approve an antidote to the anticoagulants Xarelto and Eliquis. The antidote was created for use in qualified retainers where excessive bleeding or hemorrhaging occurred in patients who used Xarelto and other drugs of its kind.
Over 9,000 qualified retainers were filed against the makers of Xarelto, including over 7,000 in Louisiana and around 1000 in both Philadelphia and Delaware.
Due to the overwhelming number of Xarelto lawsuits being filed, four bellwether qualified retainers were scheduled to begin in February of 2017.
Bayer and Johnson & Johnson agreed to a settlement payout of $775 million to settle 25,000 lawsuits against their blood thinner, Xarelto. The two pharmaceutical companies will split the cost and pay $387.5 million each.
Kevin McGill. “$775 million settlement reached in lawsuits over Xarelto blood thinner”, USA Today. Accessed May 21, 2019.
Joe Nocera. “Xarelto Settlement Is a Missed Chance to Stanch the Bleeding”, Bloomber. Accessed May 21, 2019.
WebMD. “Xarelto”, WebMd. Accessed May 21, 2019.
MedlinePlus. “Rivaroxaban”, U.S. National Library of Medicine. Accessed May 21, 2019.
Mayo Clinic. “Rivaroxaban (Oral Route)”, Mayo Clinic. Accessed May 21, 2019.
Drugs.com. “Xarelto Approval History”, Drugs.com. Accessed May 21, 2019.